|
1
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Roock W, Jonker DJ, Di Nicolantonio F,
Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M,
Piessevaux H, et al: Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic
colorectal cancer treated with cetuximab. JAMA. 304:1812–1820.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Folprecht G, Gruenberger T, Bechstein W,
Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J,
Lang H, Trarbach T, et al: Survival of patients with initially
unresectable colorectal liver metastases treated with
FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary
concept (CELIM study). Ann Oncol. 25:1018–1025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th. Wiley
-Blackwell; London: 2017
|
|
9
|
Kopetz S, Chang GJ, Overman MJ, Eng C,
Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and
McWilliams RR: Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved
chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adam R, Delvart V, Pascal G, Valeanu A,
Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F,
Ghémard O, et al: Rescue surgery for unresectable colorectal liver
metastases downstaged by chemotherapy: A model to predict long-term
survival. Ann Surg. 240:644–657; discussion 657-658.
2004.PubMed/NCBI
|
|
11
|
Tomlinson JS, Jarnagin WR, DeMatteo RP,
Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH and
D'Angelica M: Actual 10-year survival after resection of colorectal
liver metastases defines cure. J Clin Oncol. 25:4575–4580. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yedibela S, Klein P, Feuchter K, Hoffmann
M, Meyer T, Papadopoulos T, Göhl J and Hohenberger W: Surgical
management of pulmonary metastases from colorectal cancer in 153
patients. Ann Surg Oncol. 13:1538–1544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iida T, Nomori H, Shiba M, Nakajima J,
Okumura S, Horio H, Matsuguma H, Ikeda N, Yoshino I, Ozeki Y, et
al; Metastatic Lung Tumor Study Group of Japan, . Prognostic
factors after pulmonary metastasectomy for colorectal cancer and
rationale for determining surgical indications: A retrospective
analysis. Ann Surg. 257:1059–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Min BS, Kim NK, Sohn SK, Cho CH, Lee KY
and Baik SH: Isolated paraaortic lymph-node recurrence after the
curative resection of colorectal carcinoma. J Surg Oncol.
97:136–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi PW, Kim HC, Kim AY, Jung SH, Yu CS
and Kim JC: Extensive lymphadenectomy in colorectal cancer with
isolated para-aortic lymph node metastasis below the level of renal
vessels. J Surg Oncol. 101:66–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakai N, Yamaguchi T, Kinugasa Y, Shiomi
A, Kagawa H, Yamakawa Y, Numata M and Furutani A: Long-term
outcomes after resection of para-aortic lymph node metastasis from
left-sided colon and rectal cancer. Int J Colorectal Dis.
32:999–1007. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsuji A, Sunakawa Y, Ichikawa W, Nakamura
M, Kochi M, Denda T, Yamaguchi T, Shimada K, Takagane A, Tani S, et
al: Early tumor shrinkage and depth of response as predictors of
favorable treatment outcomes in patients with metastatic colorectal
cancer treated with FOLFOX plus cetuximab (JACCRO CC-05). Target
Oncol. 11:799–806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye LC, Wei Y, Zhu DX, Chen T and Xu J:
Impact of early tumor shrinkage on clinical outcome in
wild-type-KRAS colorectal liver metastases treated with cetuximab.
J Gastroenterol Hepatol. 30:674–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Venook AP, Niedzwiecki D, Lenz HJ,
Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH,
Atkins JN, et al: Effect of first-line chemotherapy combined with
cetuximab or bevacizumab on overall survival in patients with KRAS
wild-type advanced or metastatic colorectal cancer: A randomized
clinical trial. JAMA. 317:2392–2401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al: FOLFIRI plus
cetuximab versus FOLFIRI plus bevacizumab as first-line treatment
for patients with metastatic colorectal cancer (FIRE-3): a
randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, et al: PEAK: a randomized,
multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. Journal of
clinical oncology: J Clin Oncol. 21:2240–2247. 2014. View Article : Google Scholar
|
|
23
|
Poston G, Adam R and Xu J, Byrne B, Esser
R, Malik H, Wasan H and Xu J: The role of cetuximab in converting
initially unresectable colorectal cancer liver metastases for
resection. Eur J Surg Oncol. 43:2001–2011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cremolini C, Loupakis F, Antoniotti C,
Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R,
Zaniboni A, et al: Early tumor shrinkage and depth of response
predict long-term outcome in metastatic colorectal cancer patients
treated with first-line chemotherapy plus bevacizumab: Results from
phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann
Oncol. 26:1188–1194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tomasello G, Petrelli F, Ghidini M, Russo
A, Passalacqua R and Barni S: FOLFOXIRI plus bevacizumab as
conversion therapy for patients with initially unresectable
metastatic colorectal cancer: A systematic review and pooled
analysis. JAMA Oncol. 3:e1702782017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
NCCN: National Cancer Guidelines for
Patients. Colon Cancer. https://www.nccn.org/patients/guidelines/colon/September
8–2018
|
|
27
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D; Aranda Primary lesion has almost
disappeared, ; Aguilar E, Bardelli A, Benson A, Bodoky G, et al:
ESMO consensus guidelines for the management of patients with
metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016.
View Article : Google Scholar : PubMed/NCBI
|
